WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 WVE-007, an IN ...